Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma by Kapoor, Prashant, Gertz, Morie A., Laplant, Betsy, Malave, Gabriella C, Wolfe, Eric, Muchtar, Eli, Siddiqui, Mustaqeem A., Gonsalves, Wilson I, Emanuel, Angie R., Kourelis, Taxiarchis, Warsame, Rahma, Dingli, David, Buadi, Francis K., Hayman, Suzanne R., Leung, Nelson, Hwa, Yi L., Hobbs, Miriam A., Fonder, Amie, Dispenzieri, Angela, Lacy, Martha Q., Rajkumar, S. Vincent, Kumar, Shaji K.

Get full text

Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo by Chequin, Andressa, Costa, Luiz E., de Campos, Felipe F., Moncada, Angie D.B., de Lima, Lucas T.F., Sledz, Lucas R., Picheth, Guilherme F., Adami, Eliana R., Acco, Alexandra, Gonçalves, Marcos B., Manica, Graciele C.M., Valdameri, Gláucio, de Noronha, Lucia, Telles, José E.Q., Jandrey, Elisa H.F., Costa, Erico T., Costa, Fabricio F., de Souza, Emanuel M., Ramos, Edneia A.S., Klassen, Giseli

Get full text